The elevated T-maze as an experimental model of anxiety

Adamec, 1993, Lasting effects on rodent anxiety of a single exposure to a cat, Physiol. Behav., 54, 101, 10.1016/0031-9384(93)90050-P Aghajanian GK. Central 5-HT receptor subtypes: physiological responses and signal transduction mechanisms. In: Marsden CA, Heal DJ, editors. Central serotonin receptors and psychotropic drugs. Oxford: Blackwell, 1992, pp. 39–55. American Psychiatry Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: APA Press, 1994. Barret, 1993, 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions, Psychopharmacology, 112, 1, 10.1007/BF02247357 Charney, 1989, Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder, Psychiatry Res., 27, 173, 10.1016/0165-1781(89)90132-7 Connell, 1995, 5-HT2 receptors and anxiety, Behav. Pharmacol., 6, 35, 10.1097/00008877-199505001-00039 Deakin, 1991, 5-HT and mechanisms of defence, J. Psychopharmacol., 5, 305, 10.1177/026988119100500414 Deakin JFW, Guimarães FS, Graeff FG. Testing theories of anxiety in normal volunteers. In: Palomo T, Archer T, editors. Strategies for studying brain disorders, vol. 1. Depressive, anxiety and drug abuse disorders. Madrid: Editorial Complutense, 1994, pp. 211–238. Doble, 1990, RP 62203, a novel naphosultam derivative with potent and selective 5-HT2 antagonist properties: I. Binding and second messenger studies, Eur. J. Pharmacol., 183, 1744, 10.1016/0014-2999(90)92051-J File SE. Behavioural detection of anxiolytic action. In: Elliott JM, Heal DJ, Marsden CA, editors. Experimental approaches to anxiety and depression. New York: Wiley, 1992, pp. 25–44. File SE. Animal models of different anxiety states. In: Biggio G, Sanna E, Costa E, editors. GABAA Receptors and Anxiety. New York: Raven Press, 1995, pp. 93–113. Forbes, 1993, N-(1-Methyl-5-indolyl)-N′-(3-pyridyl) urea hydrochloride: the first selective 5-HT1C receptor antagonist, J. Med. Chem., 36, 1104, 10.1021/jm00060a019 Fuller, 1988, Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release, Pharmacol. Biochem. Behav., 30, 715, 10.1016/0091-3057(88)90089-5 Gloger, 1981, Treatment of spontaneous panic attacks with chlomipramine, Am. J. Psychiatry, 138, 1215, 10.1176/ajp.138.9.1215 Graeff FG. Neurotransmitters in the dorsal periaqueductal grey and animal models of panic anxiety. In: Briley M, File SE, editors. New concepts in anxiety. London: MacMillan Press, 1991, pp. 288–312. Graeff, 1996, Opposed regulation by dorsal raphe nucleus 5-HT pathways of two types of fear in the elevated T-maze, Pharmacol. Biochem. Behav., 53, 171, 10.1016/0091-3057(95)02012-8 Graeff, 1996, Dual role of 5-HT in defense and anxiety, Neurosci. Biobehav. Rev., 54, 129 Graeff, 1993, The elevated T maze, a new experimental model of anxiety and memory: effect of diazepam, Braz. J. Med. Biol. Res., 26, 67 Graeff, 1996, Role of 5-HT in stress, anxiety and depression, Pharmacol. Biochem. Behav., 54, 129, 10.1016/0091-3057(95)02135-3 Griebel, 1995, 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research, Pharmac. Ther., 65, 319, 10.1016/0163-7258(95)98597-J Griebel, 1997, Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs, Psychopharmacology, 131, 180, 10.1007/s002130050282 Guimarães, 1987, Effect of chlorimipramine and maprotiline on experimental anxiety in humans, J. Psychopharmacol., 1, 184, 10.1177/026988118700100305 Handley SL. Serotonin in animal models of anxiety: the importance of stimulus and response. In: Idzidowski C, Cowen PJ, editors. Serotonin, sleep and mental disorder. Petersfield: Wrightson Biomedical, 1991, pp. 89–115. Handley, 1993, 5-HT drugs in animal models of anxiety, Psychopharmacol., 112, 13, 10.1007/BF02247358 Handley, 1984, Effects of alpha-adrenoceptor agonists in a maze-exploration model of “fear”-motivated behaviour, Naunyn–Schmiedeberg's Arch. Pharmacol., 327, 1, 10.1007/BF00504983 Handley, 1993, Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors, Behav. Brain Res., 58, 203, 10.1016/0166-4328(93)90104-X Hetem, 1996, Effect of d-fenfluramine on human experimental anxiety, Psychopharmacology, 127, 276, 10.1007/BF02246136 Johnston, 1988, Can animal tests of anxiety detect panic-promoting agents?, Human Psychopharmacol., 3, 149, 10.1002/hup.470030213 Johnston, 1989, Yohimbine's anxiogenic action: evidence for nordrenergic and dopaminergic sites, Pharmacol. Biochem. Behav., 32, 151, 10.1016/0091-3057(89)90225-6 Kahn, 1988, Serotonin and anxiety revisited, Biol. Psychiat., 23, 189, 10.1016/0006-3223(88)90091-1 Kahn, 1986, Imipramine and chlordiazepoxide in depressive and anxiety disorders: II. Efficacy in anxious outpatients, Arch. Gen. Psychiatry, 43, 79, 10.1001/archpsyc.1986.01800010081010 Kennett, 1993, 5-HT1C receptors and their therapeutic relevance, Curr. Opin. Invest. Drugs, 2, 317 Kennett, 1988, Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors, Br. J. Pharmacol., 94, 137, 10.1111/j.1476-5381.1988.tb11508.x Kennett, 1995, Effect of SB 200646A, A 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety, Psychopharmacology, 118, 178, 10.1007/BF02245837 Kennett, 1996, Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety, Br. J. Pharmacol., 117, 1443, 10.1111/j.1476-5381.1996.tb15304.x Kennett, 1994, In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist, Brit. J. Pharmacol., 111, 797, 10.1111/j.1476-5381.1994.tb14808.x Kennett, 1997, SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist, Neuropharmacology, 36, 609, 10.1016/S0028-3908(97)00038-5 McCann, 1994, Dexfenfluramine and serotonin toxicity: further preclinical evidence that clinical caution is indicated, J. Pharmacol. Exp. Ther., 268, 792 McTavish, 1992, Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity, Drugs, 43, 713, 10.2165/00003495-199243050-00007 Mineka, 1980, Fear of snakes in wild- and laboratory-reared rhesus monkeys (Macaca mulatta), An. Learn. Behav., 8, 653, 10.3758/BF03197783 Mineka, 1984, Observational conditioning of snake fear in rhesus monkey, J. Abn. Psychol., 93, 355, 10.1037/0021-843X.93.4.355 Montgomery, 1955, The relation between fear induced by novel stimulation and exploratory behaviour, J. Comp. Physiol. Psychol., 48, 254, 10.1037/h0043788 Nichols, 1993, Novel serotonergic agents, Drug Des. Discov., 9, 299 Nozulack, 1993, SDZ SER 082, a centrally acting and selective 5-HT2C antagonist, Soc. Neurosci. Abstr., 19, 298 Nutt DJ. Anxiety and its therapy: today and tomorrow. In: Briley M, File Se, editors. New concepts in anxiety. London: MacMillan Press, 1991, pp. 1–12. Pellow, 1985, Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat, J. Neurosci. Meth., 14, 149, 10.1016/0165-0270(85)90031-7 Pesold, 1994, The septum and amygdala differentially mediate the anxiolytic effects of benzodiazepines, Brain Res., 638, 295, 10.1016/0006-8993(94)90662-9 Pesold, 1995, The central and basolateral amygdala differentially mediate the anxiolytic effects of benzodiazepines, Brain Res., 671, 213, 10.1016/0006-8993(94)01318-C Richelson, 1984, Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake, Eur. J. Pharmacol., 104, 277, 10.1016/0014-2999(84)90403-5 Rinaldi-Carmona, 1992, Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist, J. Pharmacol. Exp. Ther., 262, 759 Schweizer, 1993, Maintenance drug treatment for panic disorder. I. Results of a prospective, placebo-controlled comparizon of alprazolam and imipramine, Arch. Gen. Psychiatry, 50, 51, 10.1001/archpsyc.1993.01820130053009 Scorza, 1996, Behavioral effects of the putative anxiolytic (±)-1-(2,5-dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2) in rats and mice, Pharmacol. Biochem. Behav., 54, 355, 10.1016/0091-3057(95)02149-3 Solyom, 1994, Controlling panic attacks with fenfluramine, Am. J. Psychiat., 151, 621, 10.1176/ajp.151.4.621b Stutzmann, 1991, Are 5-HT2 antagonists endowed with anxiolytic properties in rodents?, Neurosci. Lett., 128, 4, 10.1016/0304-3940(91)90747-H Targum, 1989, Fenfluramine provocation of anxiety in patients with panic disorder, Psychiatry Res., 28, 295, 10.1016/0165-1781(89)90210-2 Treit, 1993, Anxiogenic stimuli in the elevated plus-maze, Pharmacol. Biochem. Behav., 44, 463, 10.1016/0091-3057(93)90492-C Treit, 1993, Anxiolytic effects of serotonergic interventions in the shock-probe burying test and the elevated plus-maze test, Behav. Brain Res., 54, 23, 10.1016/0166-4328(93)90045-R Viana, 1994, The elevated T-maze: an animal model of anxiety and memory, Pharmacol. Biochem. Behav., 49, 549, 10.1016/0091-3057(94)90067-1 Walk, 1957, Behavior of light- and dark-reared rats on a visual cliff, Science., 126, 80, 10.1126/science.126.3263.80-a Zangrossi, 1992, Chlordiazepoxide reduces the generalised anxiety, but not the direct responses, of rats exposed to cat odor, Pharmacol. Biochem. Behav., 43, 1195, 10.1016/0091-3057(92)90502-7 Zangrossi, 1994, Habituation and generalization of phobic responses to cat odor, Brain Res. Bull., 33, 189, 10.1016/0361-9230(94)90250-X